Apollomics Inc. (APLM) has entered into a $2.0 million unsecured convertible promissory note with Chairman and CEO Hung-Wen (Howard) Chen, providing short-term working capital to advance its clinical development programs and support general corporate operations.
The note, executed on March 30, 2026, carries a 0% interest rate and will automatically convert into Apollomics equity upon the closing of a future financing round of at least $10 million. The conversion price will be set at a 20% discount to the lowest per-share price issued in the qualifying financing. The company's independent Audit Committee and Board approved the related-party transaction, with Chen abstaining from the vote.
Apollomics said the financing decision followed a review of available capital options and a benchmarking analysis of current market terms for similar bridge transaction in the biotech sector.
The company continues to advance its lead program, Vebreltinib (APL-101), a selective c-Met inhibitor currently in Phase 2 multicohort trial for non-small cell lung cancer and other advanced tumors with c-Met alterations across the U.S. and more than 10 additional countries.
The company implemented a 1-for-100 reverse stock split on November 25, 2024.
APLM closed Tuesday's trading at $15.85, down 5.65%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.